Truvada
Encyclopedia
Tenofovir/emtricitabine, trademark Truvada, is a fixed-dose combination of two antiretroviral drug
s used for the treatment of HIV
. It consists of 300 milligrams of tenofovir and 200 milligrams of emtricitabine
. By combining the two agents into one tablet, it reduces the pill burden and increases compliance
with antiretroviral therapy. The drug has also found some potential as a preventative measure if taken daily or weekly leading up to exposure, though human clinical trials are ongoing.
In other randomized studies, emtricitabine/tenofovir DF 200 mg/300 mg once daily was an effective backbone for boosted PI-based regimens in the initial treatment of HIV-1 infection.
Emtricitabine/tenofovir DF in combination with various boosted PIs was generally well tolerated by adults with HIV-1 infection.
Truvada was developed by Gilead Sciences
and approved by the United States Food and Drug Administration in 2004.
A combination pill containing Truvada and kranthi (Sustiva) is also available and is marketed as Atripla
.
Antiretroviral drug
Antiretroviral drugs are medications for the treatment of infection by retroviruses, primarily HIV. When several such drugs, typically three or four, are taken in combination, the approach is known as Highly Active Antiretroviral Therapy, or HAART...
s used for the treatment of HIV
HIV
Human immunodeficiency virus is a lentivirus that causes acquired immunodeficiency syndrome , a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive...
. It consists of 300 milligrams of tenofovir and 200 milligrams of emtricitabine
Emtricitabine
Emtricitabine , with trade name Emtriva , is a nucleoside reverse transcriptase inhibitor for the treatment of HIV infection in adults and children....
. By combining the two agents into one tablet, it reduces the pill burden and increases compliance
Compliance (medicine)
In medicine, compliance describes the degree to which a patient correctly follows medical advice...
with antiretroviral therapy. The drug has also found some potential as a preventative measure if taken daily or weekly leading up to exposure, though human clinical trials are ongoing.
Clinical studies
The HEAT study (randomized, double-blind, placebo-matched, multicentre) showed that once-daily emtricitabine/tenofovir plus lopinavir/ritonavir or boosted atazanavir or efavirenz were effective in the initial treatment of patients with HIV-1 infection (with screening plasma HIV-1 RNA levels of ≥1,000,000 copies/mL in ACTG 5202).In other randomized studies, emtricitabine/tenofovir DF 200 mg/300 mg once daily was an effective backbone for boosted PI-based regimens in the initial treatment of HIV-1 infection.
Emtricitabine/tenofovir DF in combination with various boosted PIs was generally well tolerated by adults with HIV-1 infection.
Truvada was developed by Gilead Sciences
Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics. For many years since the company was founded, the company concentrated primarily on antiviral drugs to treat patients infected with HIV, hepatitis B or influenza. In 2006, Gilead acquired two...
and approved by the United States Food and Drug Administration in 2004.
A combination pill containing Truvada and kranthi (Sustiva) is also available and is marketed as Atripla
Atripla
Emtricitabine/tenofovir/efavirenz is a fixed-dose combination drug for the treatment of HIV infection. It combines Gilead Sciences's tenofovir and emtricitabine with Bristol-Myers Squibb's efavirenz into a fixed-dose pill...
.
External links
- Truvada website, run by Gilead Sciences
- Global iPrEx study website